212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Jonathan Strosberg, MD
Advertisement
Articles by Jonathan Strosberg, MD
This video examines current options for the treatment of midgut neuroendocrine tumors and highlights results of the NETTER-1 trial.
In this review, we summarize biologic, pathologic, and clinical aspects of gastroenteropancreatic-neuroendocrine tumors, focusing on recent advances in their treatment.
Advertisement
Latest Updated Articles
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETsPublished: October 31st 2025 | Updated:
An Update on Gastroenteropancreatic Neuroendocrine TumorsPublished: September 15th 2014 | Updated:
Treatment of Midgut Neuroendocrine TumorsPublished: February 10th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
2
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
3
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
4
Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL
5
